CARLSMED INC

CARLNASDAQ

🏆 #2822 by market capUS Equity

$13.80▲ $0.06 (+0.40%)

Live

1h▼ 1.3%

24h▲ 0.4%

7d▲ 1.5%

14d▲ 8.2%

30d▲ 15.0%

1y▲ 3.7%

🏦Market Cap

$375M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

75.9%

High

💵FCF Margin

—

⚖️P/S Ratio

6.6x

Fair

Otter Score

Fair

Trading Snapshot

Day Range: $13.74 – $13.99
52-Week Range: $8.50 – $17.19
Volume: $3.09B
Avg Volume: $3.91B
Shares Outstanding: 27.2M
Next Earnings: Oct 25, 2026

Fundamentals Snapshot

Annual Revenue: $51M
Last Q Revenue: $19M
P/E Ratio: —
P/S Ratio: 6.6x
EPS (TTM): $-1.31
Dividend Yield: —

Why Investors Own CARL

✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 30% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$51M▲ +17.7% YoY

Gross Margin (TTM)

65.0%▼ −0.2% YoY

Operating Income (TTM)

$16M▲ +17.7% YoY

Free Cash Flow (TTM)

$15M▲ +17.7% YoY

About CARLSMED INC

Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

🦦